nach oben

Current Heart Failure Reports

Erschienen in:

01.10.2015 | Biomarkers of Heart Failure (W.H.W. Tang, Section Editor

Novel Biomarker Approaches for Managing Patients With Cardiac Transplantation

verfasst von: Peter J. Kennel, P. Christian Schulze

Erschienen in: Current Heart Failure Reports | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Despite major advances in the medical care of patients following heart transplantation (HTx) and a steady increase in long-term survival, allograft surveillance is still based on endomyocardial biopsy, the gold standard since the 1970s. This invasive procedure calls for less burdening and more cost-effective approaches. In recent years, impressive progress has been made in utilizing blood-based biomarkers for the diagnosis and management of diseases in a variety of fields. Hence, a number of trials have been performed testing the usefulness of circulating molecules or other technical methods to overcome the need for surveillance myocardial biopsy in HTx patients. Here, we review current approaches and the state of research on novel biomarkers for the management of patients following heart transplantation.

Adhyaru BB, Jacobson TA. New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk: a comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia. Cardiol Clin. 2015;33:181–96.CrossRefPubMed

Akat KM, Moore-McGriff D, Morozov P, Brown M, Gogakos T, Correa Da Rosa J, et al. Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers. Proc Natl Acad Sci U S A. 2014;111:11151–6.PubMedCentralCrossRefPubMed

Arnau-Vives MA, Almenar L, Hervas I, Osa A, Martinez-Dolz L, Rueda J, et al. Predictive value of brain natriuretic peptide in the diagnosis of heart transplant rejection. J Heart Lung Transplant. 2004;23:850–6.CrossRefPubMed

Battes LC, Caliskan K, Rizopoulos D, Constantinescu AA, Robertus JL, Akkerhuis M, et al. Repeated measurements of NT-pro-B-type natriuretic peptide, troponin T or C-reactive protein do not predict future allograft rejection in heart transplant recipients. Transplantation. 2015;99:580–5.CrossRefPubMed

Borozdenkova S, Westbrook JA, Patel V, Wait R, Bolad I, Burke MM, et al. Use of proteomics to discover novel markers of cardiac allograft rejection. J Proteome Res. 2004;3:282–8.CrossRefPubMed

Chance JJ, Segal JB, Wallerson G, Kasper E, Hruban RH, Kickler TS, et al. Cardiac troponin T and C-reactive protein as markers of acute cardiac allograft rejection. Clin Chim Acta. 2001;312:31–9.CrossRefPubMed

Chen W, Peng W, Huang J, Yu X, Tan K, Chen Y, et al. Microarray analysis of long non-coding RNA expression in human acute rejection biopsy samples following renal transplantation. Mol Med Rep. 2014;10:2210–6.PubMed

8.•

Cohen Freue GV, Meredith A, Smith D, Bergman A, Sasaki M, Lam KK, et al. Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation. PLoS Comput Biol. 2013;9, e1002963. Bioinformatic approach to discover valid biomarkers.PubMedCentralCrossRefPubMed

Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914–56.CrossRefPubMed

10.

Crespo-Leiro MG, Stypmann J, Vanhaecke J. Utility of Gene Expression Profiling Test (GEP) score instability to predict future clinical outcomes in heart transplant: results from the CARGO 2 European-Based Multicenter Trial. J Heart Lung Transplant. 2013;32(4):S113–4.CrossRef

11.•

Daly KP. Circulating donor-derived cell-free DNA: a true biomarker for cardiac allograft rejection? Ann Transl Med. 2015;3:47. Introduces the concept of dscfDNA.PubMedCentralPubMed

12.•

De Vlaminck I, Valantine HA, Snyder TM, Strehl C, Cohen G, Luikart H, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014;6, 241ra277. dscfDNA trial.CrossRef

13.•

Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006;6:150–60. Allomap key trial.CrossRefPubMed

14.

Deng MC, Elashoff B, Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, et al. Utility of gene expression profiling score variability to predict clinical events in heart transplant recipients. Transplantation. 2014.

15.

Dengler TJ, Zimmermann R, Braun K, Muller-Bardorff M, Zehelein J, Sack FU, et al. Elevated serum concentrations of cardiac troponin T in acute allograft rejection after human heart transplantation. J Am Coll Cardiol. 1998;32:405–12.CrossRefPubMed

16.•

Duong Van Huyen JP, Tible M, Gay A, Guillemain R, Aubert O, Varnous S, et al. MicroRNAs as non-invasive biomarkers of heart transplant rejection. Eur Heart J. 2014;35:3194–202. miRNA trial.CrossRefPubMed

17.

FDA USFDA. 510(k) Substantial equivalence determination decision summary - http://www.accessdata.fda.gov/cdrh_docs/reviews/K073482.pdf. 2008.

18.

Garrido IP, Pascual-Figal DA, Nicolas F, Gonzalez-Carrillo MJ, Manzano-Fernandez S, Sanchez-Mas J, et al. Usefulness of serial monitoring of B-type natriuretic peptide for the detection of acute rejection after heart transplantation. Am J Cardiol. 2009;103:1149–53.CrossRefPubMed

19.•

Hidestrand M, Tomita-Mitchell A, Hidestrand PM, Oliphant A, Goetsch M, Stamm K, et al. Highly sensitive noninvasive cardiac transplant rejection monitoring using targeted quantification of donor-specific cell-free deoxyribonucleic acid. J Am Coll Cardiol. 2014;63:1224–6. dscfDNA trial.CrossRefPubMed

20.

Kienzl K, Sarg B, Golderer G, Obrist P, Werner ER, Werner-Felmayer G, et al. Proteomic profiling of acute cardiac allograft rejection. Transplantation. 2009;88:553–60.CrossRefPubMed

21.

Kirchhoff W, Gradaus R, Stypmann J, Deng MC, Tian TD, Scheld HH, et al. Vasoactive peptides during long-term follow-up of patients after cardiac transplantation. J Heart Lung Transplant. 2004;23:284–8.CrossRefPubMed

22.

Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A, et al. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res. 2014;114:1569–75.CrossRefPubMed

23.

Lampert BC, Teuteberg JJ, Shullo MA, Holtz J, Smith KJ. Cost-effectiveness of routine surveillance endomyocardial biopsy after 12 months post-heart transplantation. Circ Heart Fail. 2014;7:807–13.CrossRefPubMed

24.••

Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report—2014; focus theme: retransplantation. J Heart Lung Transplant. 2014;33:996–1008. Statistics for cardiac allograft survival and incidence of rejection episodes.CrossRefPubMed

25.

Maisel A, Mueller C, Adams Jr K, Anker SD, Aspromonte N, Cleland JG, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824–39.CrossRefPubMed

26.

Mullen JC, Bentley MJ, Scherr KD, Chorney SG, Burton NI, Tymchak WJ, et al. Troponin T and I are not reliable markers of cardiac transplant rejection. Eur J Cardiothorac Surg. 2002;22:233–7.CrossRefPubMed

27.

OPTN. Organ Procurement Transplantation Network - http://optn.transplant.hrsa.gov/ 2014.

28.

Patel PC, Hill DA, Ayers CR, Lavingia B, Kaiser P, Dyer AK, et al. High-sensitivity cardiac troponin I assay to screen for acute rejection in patients with heart transplant. Circ Heart Fail. 2014;7:463–9.CrossRefPubMed

29.•

Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med. 2010;362:1890–900. Allomap key trial.CrossRefPubMed

30.••

Qian WJ, Jacobs JM, Liu T, Camp 2nd DG, Smith RD. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics. 2006;5:1727–44. Illustrates challenges and pitfalls in the development for protein biomarkers.PubMedCentralCrossRefPubMed

31.

Strimbu KandTavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5:463–6.CrossRef

32.

Subherwal S, Kobashigawa JA, Cogert G, Patel J, Espejo M, Oeser B. Incidence of acute cellular rejection and non-cellular rejection in cardiac transplantation. Transplant Proc. 2004;36:3171–2.CrossRefPubMed

33.

Sukma Dewi I, Torngren K, Gidlof O, Kornhall B, Ohman J. Altered serum miRNA profiles during acute rejection after heart transplantation: potential for non-invasive allograft surveillance. J Heart Lung Transplant. 2013;32:463–6.CrossRefPubMed

34.

Wang K, Liu F, Zhou LY, Long B, Yuan SM, Wang Y, et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res. 2014;114:1377–88.CrossRefPubMed

35.

Wu AH, Johnson ML, Aaronson KD, Gordon D, Dyke DB, Koelling TM. Brain natriuretic peptide predicts serious cardiac allograft rejection independent of hemodynamic measurements. J Heart Lung Transplant. 2005;24:52–7.CrossRefPubMed

Titel: Novel Biomarker Approaches for Managing Patients With Cardiac Transplantation
verfasst von: Peter J. Kennel
P. Christian Schulze
Publikationsdatum: 01.10.2015
Verlag: Springer US
Erschienen in: Current Heart Failure Reports / Ausgabe 5/2015
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-015-0269-1

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

The Current and Potential Clinical Relevance of Heart Failure Biomarkers

Epidemiology of Right Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction

Determined to Fail—the Role of Genetic Mechanisms in Heart Failure

Cardiometabolic Disease Leading to Heart Failure: Better Fat and Fit Than Lean and Lazy